BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 28
• 29
• 30

• Business

  Celgene Corporation to Pump $45 Million into Quanticel to Discover Cancer Drugs, Gets Option to Acquire

  November 4, 2011

   · 

  5 min read
• Drug Development

  Rexahn Pharmaceuticals, Inc.'s Serdaxin(R) Disappoints in Phase II Trial for Major Depressive Disorder

  November 4, 2011

   · 

  4 min read
• Drug Development

  Presidio Pharmaceuticals, Inc. Announces Clinical Proof-of-Concept Data for its First HCV NS5A Inhibitor, PPI-461, and Initiation of Clinical Testing for its Second-Generation NS5A Inhibitor, PPI-668

  November 4, 2011

   · 

  1 min read
• Sanofi (France) Accelerates Development of New Lantus Formulation

  November 4, 2011

   · 

  1 min read
• FDA

  FDA Approves Bayer AG/Johnson & Johnson’s Stroke Drug Xarelto But Adds a Black Box Warning

  November 4, 2011

   · 

  13 min read
• Policy

  VIVUS, Inc. Qnexa Secures FDA Approval for NDA Filing

  November 4, 2011

   · 

  8 min read
• Drug Development

  RegeneRx Biopharmaceuticals, Inc. Reports Positive Data with RGN-259 in Phase 2 Dry Eye Trial

  November 4, 2011

   · 

  7 min read
• Business

  InterMune, Inc. Reports Third Quarter 2011 Financial Results and Business Highlights

  November 4, 2011

   · 

  8 min read
• Drug Development

  Bristol-Myers Squibb Company Release: New 12 Week, Interferon-Free Treatment Arms Added to All-Oral Combination Study of PSI-7977 and Daclatasvir (BMS-790052) for HCV Genotype 1

  November 4, 2011

   · 

  1 min read
• Business

  Lannett Company, Inc. Reports Improved Results for Fiscal 2012 First Quarter

  November 4, 2011

   · 

  1 min read